UCB RECEIVES POSITIVE OPINION FOR THE USE OF KEPPRA AS MONOTHERAPY IN EUROPE

UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra (levetiracetam) as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Euronext